vTv Therapeutics (VTVT) investor relations material

Executive summary

• Nine-month revenue was $36.8M from the Newsoara upfront fee and G42 license revenue; Q3 revenue was $0.

• CATT1 completed enrollment with 166 participants randomized; topline results are expected mid-2027.

• Cash and cash equivalents were $77.2M at September 30, 2026; FDA granted Orphan Drug Designation to investigational HPPD for sickle cell disease.

Financial highlights

• Q3 2026 revenue was $0; operating expenses were $12.4M, including R&D of $7.5M and G&A of $4.9M.

• Q3 net loss attributable to common shareholders was $11.6M, or $0.94 per share, versus $8.7M, or $1.08 per share, in Q3 2025.

• Nine-month revenue was $36.8M versus $0; operating expenses were $39.9M versus $24.9M, and operating loss was $3.1M versus $24.9M.

• Nine-month net loss attributable to common shareholders was $0.5M versus $19.8M; loss per share was $0.04 versus $2.80.

Outlook and guidance

• CATT1 topline results are expected mid-2027; further registrational studies of cadisegliatin in T1D are expected to start in 2027.

• Available cash is expected to fund operations through the anticipated CATT1 readout; continued losses and negative operating cash flow mean additional capital will be needed for operations and trials.

• A supportive thorough QT study is in development; the G42-partnered T2D study is expected to begin screening in H2 2027.

• Hybrid CATT1 is intended to inform design and operations of future Phase 3 research in people with T1D using hybrid closed-loop systems.